Antivirals Flashcards
Patients being treated for HIV should be on at least ______ drugs.
3
typically 2 NRTIs and a 3rd drug
What is the MOA of NRTIs (Nuceloside Reverse Transcriptase Inhibitors)?
Eliminates action of reverse transcriptase which inhibits the virus from transcribing RNA to DNA
What type of toxicity can NRTIs cause?
Mitochondrial
Off target inhibition of mitochondrial DNA polymerase
S/s of NRTIs mitochondrial toxcity:
Peripheral neuropathy Lipodystrophy (lipoatrophy) Lactic acidosis Hepatic steatosis Pancreatitis
How are NRTIs eliminated?
Renally
Which NRTI should be used if a patient has renal dysfunction?
Abacavir
The NRTIs, Lamivudine and emtricitabine are very commonly used and have _____ toxicity risk.
Minimal
The NRTI, tenofovir, carries which type of toxicity risk?
Nephrotoxicity
The NRTI, abacavir, has which AE?
HSR (pts with HLA B-5701 allele are at greater risk)
Increased risk of MI
Zidovudine (AZT), one of the first NRTIs is still used in patients who have multiple _____ _____ and may cause ______.
drug resistance
anemia, neutropenia (d/t BM suppression)
What is the largest concern with patients on NNRTIs (Non-nucleotide Reverse Transcriptase Inhibitors)?
DI
CYP450 substrates and induce CYP3A4
SE of NNRTIs include:
rash, increased transaminases
What is concern is associated with the long half lives of NNRTIs like Efavirenz?
Patients will typically be on two NRTIs and an NNRTI, if regimen is stopped, the NRTIs will exit the body faster than the NNRTI which could have a half life up to 3 weeks. Having only the NNRTI in the body can lead to drug resistance by the virus
AE of the NNRTI Efavirenz include:
Teratogenic in 1st trimester
CNS SE
False positive cannabinoid and benzo tests
AE of NNRTI Nevirapine:
Hepatotoxicity secondary to HSR
Stevens-Johnson syndrome
AE of the NNRTI Etravirine:
2nd gen
Induces CYP3A4, inhibits 2C9(incr warfarin levels) and 2C19 (prevents activation of plavix)
What is the pharmokinetic enhancement of drug levels called?
Boosting
Protease inhibitors: lopinavir, saquinavir, darunavir, and tipranavir are always _______
Nelfinavir is _____ ______.
boosted
never boosted
How does the PI Ritonavir work to boost other PI’s?
Ritonavir is a potent inhibitor of CYP3A4, PI’s are substrates of CYP3A4. By inhibiting CYP3A4 this increases the bioavailability of PIs, decreases elimination of PIs, and results in increased efficacy, and/or a longer dosing interval
(Rotanavir has effect on HIV replication, was used at higher doses to treat HIV in the ‘90’s)
Common DI associated with Ritonavir:
CYP3A4 substrates (increase levels of those drugs also) Inhibits CYP2D6
Protease Inhibitors DI’s are related to:
Substrates of CYP3A4
Inhibitors of CYP3A4
SE of PI use:
Dyslipidemia
Increased glucose
GI intolerance
Which drugs are CI for patients using PI’s?
Midazolam, triazolam Rifampin (potent inducer of 3A4=cancel out effect of ritonavir) Simvastatin, lovastatin Fluticasone St. John's Wort
The PI Atazanavir should not be used with:
acid suppressing agents. Atazanavir needs acidic environment to be absorbed
Which drugs required dose adjustments in patients using PI’s?
Rifabutin Clarithromycin Atorvastatin Oral contraceptives Voriconazole, ketoconazole Sildenafil, vardenafil, tadalafil Anticonvulsants
Which PK enhancer/booster works by inhibiting CYP3A4 but has no effect of HIV replication?
Cobicistat
While ritonavir has mainly lipid and GI concerns what potential AE dose cobicistat have?
Renal AEs
How do the Integrase Inhibitors Raltegravir and Elvitegravir differ?
Raltegravir is metabolized by the glucoronidation pathway so is not renally eliminated and not metabolized by CYP3A4.
Elvitegravir is metabolized by 3A4 and usually boosted by Cobicistat
Which type of HIV meds are given to patients who do not have other options?
Fusion inhibitors
CCR5 Inhibitors
How does the fusion inhibitor Enfuviritide work, how is it administered, AE, metabolism?
Binds to the gp41 rc to prevent fusion
Injection
AE: injection site reactions
Metabolized via non-CYP450 pathways